Latest news with #JonathanJavitt
Yahoo
3 days ago
- Health
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
01-08-2025
- Business
- Miami Herald
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team
Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the nation's leading financial media platform, proudly announces the broadcast of Show #682, airing this evening at 9:30 PM PST on Bloomberg Television as sponsored programming. This episode showcases transformative companies driving innovation across artificial intelligence, veterinary health, blockchain, healthcare SaaS, and pharmaceutical sectors. Featured Interviews on Episode #682 Include: - DataVault Holdings Inc. (NASDAQ:DVLT)CEO Nathaniel Bradley highlights the company's enterprise expansion, announcing the debut of AI agents powered by IBM This breakthrough enables corporate clients to securely monetize data using compliant, intelligent automation. DataVault AI's growing partnerships with IBM and other tech leaders demonstrate its position at the forefront of AI + Web3 convergence-empowering businesses to unlock value from untapped data assets. - PetVivo Holdings Inc. (NASDAQ:PETV)PetVivo continues its rapid commercial rollout of SPRYNG with OsteoCushion Technology, now adopted by over 1,200 veterinary clinics across the United States. The company is also making strategic inroads into the equine space through its new partnership with Commonwealth Thoroughbreds-aimed at advancing equine joint wellness and performance across top-tier racing circuits. This milestone reflects PetVivo's growing leadership in the $3B+ animal therapeutics market, with SPRYNG providing a drug-free, minimally invasive solution to joint pain in companion and performance animals. - Health In TechHealth In Tech presents its disruptive approach to benefits administration via an end-to-end SaaS platform designed for brokers, employers, and TPAs. The solution's intuitive interface and real-time quoting tools deliver speed, efficiency, and scalability for today's healthcare benefits landscape. - FLOKILeaders from FLOKI discuss their growing DeFi ecosystem and global presence, with recent expansions into financial education tools, community governance, and real-world payment infrastructure. - NRx Pharmaceuticals (NASDAQ:NRXP)CEO Dr. Jonathan Javitt offers an update on the company's late-stage pharmaceutical developments for bipolar depression, PTSD, and other CNS disorders, while continuing to advance FDA engagement for its proprietary pipeline. National TV Commercial Support: High-frequency national commercials and campaigns are airing in conjunction with the show for: NRx PharmaceuticalsArriveAISustainable Green Team (SGTM)MUSQ - The Music ETF Campaigns are focused on national television and the #1 NYC DMA, targeting high-investor-density zones and financial news audiences. Cross-Platform Distribution & Outdoor Exposure: All interviews are distributed via New to The Street's YouTube channel (3.1M+ subscribers) and promoted across LinkedIn, Twitter/X, Instagram, and Facebook. Clients also receive billboard exposure across Times Square, Wall Street, and NYC Financial District bus shelters, with additional reach through syndicated earned media on ABC, NBC, and CBS local affiliates. July Performance: A Record Month for Client Renewals July saw 9 clients signing new or renewed media agreements across broadcast, digital, and outdoor campaigns - driven by demand for New to The Street's unmatched national visibility and investor engagement platform. These results position the network as the leading multi-channel awareness engine for small- to mid-cap growth companies. About New to The Street:New to The Street is a premier television business brand broadcasting sponsored programming on Fox Business and Bloomberg Television. With a loyal YouTube following of over 3.1 million subscribers, iconic outdoor billboard access, and strong earned media distribution, New to The Street delivers a 360-degree media solution for public and private companies seeking scale, credibility, and conversion. Media Contact:Monica BrennanMonica@ SOURCE: New to The Street
Miami Herald
23-06-2025
- Business
- Miami Herald
New to The Street Show #673 Airs Nationwide on Bloomberg TV - Saturday, June 21 at 6:30 PM EST Featuring FLOKI, NRX Pharmaceuticals (NASDAQ:NRXP), MUSQ - The Music ETF (NYSE:MUSQ), Health In Tech (NASDAQ:HIT), and Vita Bella
The show is sponsored by The Sustainable Green Team's (OTC:SGTM) Waterless Garden NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / New to The Street, the nation's leading financial television series, announces the nationwide broadcast of Episode #673 on Saturday, June 21 at 6:30 PM EST across Bloomberg Television as sponsored programming. Sponsored by The Sustainable Green Team's (OTC PINK:SGTM) Waterless Garden, this week's show features five innovators from across the Web3, biotech, ETF, insurtech, and wellness industries. The program includes exclusive coverage of FLOKI's June 30 mainnet launch of Valhalla, one of the most anticipated metaverse game deployments in crypto. In addition to its national TV footprint, New to The Street also delivers major reach via its rapidly growing YouTube platform, New to The Street TV, which now has over 2.77 million subscribers and features full interviews and behind-the-scenes content: Featured Segments Include: FLOKI - The people's crypto shares key updates including the June 30 launch of Valhalla, its Norse mythology-based metaverse game, and continued growth of its no-code tokenization platform, Pharmaceuticals (NASDAQ:NRXP) - CEO Dr. Jonathan Javitt discusses progress on the company's FDA-designated drug candidates and its national rollout of interventional mental health services through HOPE - The Music ETF (NYSE:MUSQ) - The only ETF focused entirely on the music industry, MUSQ delivers a new opportunity for investors to gain exposure to global music In Tech (NASDAQ:HIT) - The insurtech company digitizing benefits through real-time quoting, advanced APIs, and simplified plan Bella - A wellness brand combining science-based skincare and nutrition for a premium, longevity-focused lifestyle product suite. New to The Street airs weekly on Bloomberg Television (Saturdays at 6:30 PM EST) and FOX Business (Mondays at 10:30 PM EST), reaching over 225 million homes and backed by outdoor Times Square billboards, earned media placement on ABC/NBC/CBS affiliates, and one of the fastest-growing business YouTube channels in the industry. About the Featured Companies About FLOKI FLOKI is the people's cryptocurrency and the utility token of the Floki Ecosystem, with over 550,000 holders worldwide. Built around utility, community, philanthropy, and marketing, FLOKI has launched campaigns seen by billions. The upcoming June 30, 2025 mainnet launch of Valhalla, its metaverse MMORPG, marks a milestone in its global | @RealFlokiInu About TokenFi TokenFi is a no-code platform empowering users to create and tokenize crypto and real-world assets with ease, targeting the multi-trillion-dollar asset tokenization | @tokenfi About Valhalla Valhalla is FLOKI's metaverse MMORPG where users explore, collect, and battle creatures called Veras in a decentralized, play-to-earn economy. The mainnet goes live June 30, About NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) NRX Pharmaceuticals is developing NMDA-targeted therapeutics to treat CNS conditions including suicidal bipolar depression, PTSD, and chronic pain. Its lead drug, NRX-101, has FDA Breakthrough Therapy Designation and is moving toward accelerated approval. The company is also advancing NRX-100, a preservative-free ketamine formulation with Fast Track About HOPE Therapeutics, Inc. HOPE Therapeutics, a subsidiary of NRX Pharmaceuticals, is establishing a national network of clinics to deliver ketamine, TMS, and digital therapies for patients with suicidal depression and related About MUSQ - The Music ETF (NYSE:MUSQ) MUSQ offers diversified exposure to the global music economy, including streaming platforms, music publishers, labels, and live event companies-all in one About Health In Tech (NASDAQ:HIT) Health In Tech is a disruptive insurtech streamlining plan administration through real-time quoting tools, automation, and API-driven About Vita Bella Vita Bella is a premium wellness and skincare brand blending science and beauty through clean, longevity-driven formulations for skin and body About The Sustainable Green Team (OTC:SGTM) The Sustainable Green Team is an industry leader in environmentally responsible solutions. Its Waterless Garden system redefines landscaping through sustainable, soil-enhancing mulch that requires no irrigation-backed by proprietary soil tech and adopted across eco-conscious public and private Media Contact:Monica BrennanDirector of Media RelationsMonica@ Explore more: on YouTube (2.77M+ subscribers): SOURCE: New To The Street
Associated Press
12-06-2025
- Business
- Associated Press
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', 'NRx' or the 'Company'), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ('HOPE,' or the 'Company'), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference. Please request 1:1 meetings on the HCW conference website listed below. Event Details: About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. ( ), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
Yahoo
12-06-2025
- Business
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference. Please request 1:1 meetings on the HCW conference website listed below. Event Details: Date: Presentation available on-demand Monday, June 16, beginning at 7:00 a.m. ET for registered conference attendees Registration: H.C. Wainwright 6th Annual Neuro Perspectives Registration NRx Website: NRx Events About NRx Pharmaceuticals, Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Therapeutics, Inc. ( a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information:Matthew Duffy Brian Korb Co-CEO, Hope Therapeutics, Inc. Managing Partner, astr partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 mduffy@ View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
